anti cd47 d3o7p rabbit mab Search Results


rabbit monoclonal anti cd47 antibody  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc rabbit monoclonal anti cd47 antibody
Rabbit Monoclonal Anti Cd47 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/CD47+Rabbit+mAb/pm38627199-33-1-7
Average 95 stars, based on 1 article reviews
rabbit monoclonal anti cd47 antibody - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
rabbit intracellular anti cd47  (Affinity Biosciences)
86
Affinity Biosciences rabbit intracellular anti cd47
Rabbit Intracellular Anti Cd47, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/anti+cd47+intracellular+rabbit/pm40737399-435-14-20
Average 86 stars, based on 1 article reviews
rabbit intracellular anti cd47 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
anti cd47  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc anti cd47
Anti Cd47, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/CD47+Rabbit+mAb/pmc12756553-73-69-72
Average 94 stars, based on 1 article reviews
anti cd47 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
anti p53 rabbit mab  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc anti p53 rabbit mab
Anti P53 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/p53+Antibody/pm40379682-447-6-21
Average 97 stars, based on 1 article reviews
anti p53 rabbit mab - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
slc3a2 4f2hc cd98  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc slc3a2 4f2hc cd98
Slc3a2 4f2hc Cd98, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/4F2hc%2FCD98+Rabbit+mAb/pmc09290189-689-38-40
Average 93 stars, based on 1 article reviews
slc3a2 4f2hc cd98 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
anti pd l1 e1l3n rabbit mab  (Cell Signaling Technology Inc)
98
Cell Signaling Technology Inc anti pd l1 e1l3n rabbit mab
a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and <t>PD-L1</t> in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.
Anti Pd L1 E1l3n Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/PD-L1+XP+Rabbit+mAb/pmc12084640-439-12-21
Average 98 stars, based on 1 article reviews
anti pd l1 e1l3n rabbit mab - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
integrin beta 1  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc integrin beta 1
a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and <t>PD-L1</t> in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.
Integrin Beta 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/Integrin+beta1+Rabbit+mAb/pmc09290189-689-16-20
Average 95 stars, based on 1 article reviews
integrin beta 1 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
parp rabbit mab  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc parp rabbit mab
a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and <t>PD-L1</t> in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.
Parp Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/PARP+Rabbit+mAb/pm41534899-297-33-53
Average 95 stars, based on 1 article reviews
parp rabbit mab - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
gst rabbit antibody  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc gst rabbit antibody
a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and <t>PD-L1</t> in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.
Gst Rabbit Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/GST-Tag+Rabbit+mAb/pm41534899-297-45-53
Average 96 stars, based on 1 article reviews
gst rabbit antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti human pan keratin c11 mouse mab  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc anti human pan keratin c11 mouse mab
a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and <t>PD-L1</t> in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.
Anti Human Pan Keratin C11 Mouse Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/Pan-Keratin+Mouse+mAb/pm40379682-459-20-30
Average 95 stars, based on 1 article reviews
anti human pan keratin c11 mouse mab - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
caspase 3 rabbit mab  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc caspase 3 rabbit mab
a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and <t>PD-L1</t> in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.
Caspase 3 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd47+d3o7p+rabbit+mab/Caspase-3+Rabbit+mAb/pm41534899-297-18-53
Average 96 stars, based on 1 article reviews
caspase 3 rabbit mab - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and PD-L1 in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.

Journal: Nature Communications

Article Title: USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity

doi: 10.1038/s41467-025-59621-5

Figure Lengend Snippet: a Diagrammatic treatment plan for immunocompetent C57BL/6J mice with LLC tumors. Mice were implanted with 2 × 10 6 LLC cells and treated with Vehicle, ML364 (5 mg/kg daily for 18 doses), anti-PD-1 mAb (100 μg/mouse every three days for 6 doses), or combination therapy. i.p., intraperitoneal; s.c., subcutaneous. b Tumor volume in different treatment groups was assessed using calipers, and the tumor growth curve was generated. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. c Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Log-rank test. n = 8 (Vehicle); 8 (ML364); 8 (anti-PD-1 mAb) and 10 (Combined therapy) mice. d A schematic treatment plan for immunocompetent C57BL/6J mice bearing 2 × 10 6 LLC tumors. Mice were treated with a control vehicle, USP2 inhibitor (ML364, 30 mg/kg for 18 doses), anti-PD-1 mAb (200 μg per mouse for 6 doses), or combined treatment, respectively. e Tumor volume in the different treatment groups was measured using calipers, and the corresponding tumor growth curve was generated. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. f Kaplan–Meier survival curves for C57BL/6J bearing LLC tumors with indicated treatments. Vehicle (n = 9), ML364 (n = 8), PD-1 mAb (n = 8), ML364 & PD-1 mAb (n = 13) mice per group. Log-rank test. g IHC staining for CD47 and PD-L1 in LLC tumors from C57BL/6J mice treated with indicated reagents. Scale bar, 50 μm. h , i Quantification for CD47 ( h ) and PD-L1 ( i ) positive cells. Each point represents the average counts of positive cells within three high-power fields. For ( h ) and ( i ), unpaired two-tailed Student’s t -test. n = 5 mice per group. Log-rank test for ( c , f ). Data are shown as the mean ± SD. P < 0.05 was considered statistically significant. Source data are provided as the Source Data file.

Article Snippet: Anti-CD47 (D3O7P) Rabbit mAb (63000, 1:2000), anti-p53 Rabbit mAb (9282T, 1:2000), and anti-PD-L1 (E1L3N) Rabbit mAb (13684, 1:2000) were purchased from Cell Signaling Technology.

Techniques: Generated, Control, Immunohistochemistry, Two Tailed Test